Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nilotinib nanoparticle formulation - Xspray Pharma

Next Previous
Drug Profile

Nilotinib nanoparticle formulation - Xspray Pharma

Alternative Names: HyNap-Nilo; RightSize nilotinib; XS 003

Latest Information Update: 12 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xspray Pharma
  • Class Anilides; Aniline compounds; Antineoplastics; Benzamides; Fluorinated hydrocarbons; Imidazoles; Ketones; Pyridines; Pyrimidines; Small molecules; Toluenes
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myelomonocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Chronic myeloid leukaemia

Most Recent Events

  • 09 Jul 2024 Xspray Pharma plans to file NDA for Chronic myeloid leukemia in USA in the first half of 2025
  • 21 Nov 2023 Nilotinib nanoparticle formulation is still in phase-I trials for Chronic myeloid leukemia (In volunteers) in United Kingdom
  • 21 Nov 2023 Pharmacokinetics data from phase-I trial in Chronic myeloid leukemia (In volunteers) released by Xspray Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top